Boston Scientific director granted deferred stock units

Boston Scientific director Cathy R. Smith received two grants of deferred stock units as part of her non-employee director compensation.

Rhea-AI Filing Summary

Boston Scientific director Cathy R. Smith received two grants of deferred stock units as part of her non-employee director compensation. She acquired 556 deferred stock units valued at approximately $42,419.50 as an equity award and 323 deferred stock units valued at approximately $24,662.50 in lieu of yearly cash compensation. Each deferred stock unit represents a commitment to issue one share of common stock. Both grants are prorated from her appointment date to the 2026 annual meeting and vest in full at the next annual meeting, with shares delivered after she leaves Board service under the company’s deferred compensation plan.

Insider Trade Summary

Grant/Award: 879 shares

Grant/Award 2 txns

Insider Smith Cathy R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	556	$0.00	$0.00
Grant/Award	Deferred Stock Units	323	$0.00	$0.00

Holdings After Transaction: Deferred Stock Units — 879 contracts (Direct)

Footnotes (3)

1. F1. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
2. F2. Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $42,419.50 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.
3. F3. Grant of deferred stock units in lieu of 100% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cathy R. Smith report for Boston Scientific (BSX)?

Cathy R. Smith reported two grants of deferred stock units as a Boston Scientific non-employee director. She received 556 units as an equity award and 323 units in lieu of cash fees, reflecting her prorated Board compensation.

How many deferred stock units did Cathy R. Smith receive from Boston Scientific (BSX)?

Cathy R. Smith received 879 deferred stock units in total, consisting of 556 units as an equity award and 323 units replacing cash compensation. Each unit represents a future share of Boston Scientific common stock under the director compensation program.

What is the dollar value of Cathy R. Smith’s deferred stock unit grants at Boston Scientific (BSX)?

The grants reflect values of about $42,419.50 and $24,662.50, based on the closing stock price on the grant date. These correspond to prorated portions of the company’s annual equity award and cash retainer for non-employee directors.

When do Cathy R. Smith’s Boston Scientific (BSX) deferred stock units vest?

Both deferred stock unit grants vest in full at the next annual meeting of stockholders. The awards are prorated from her appointment date through the 2026 annual meeting under the company’s non-employee director compensation program.

When will shares underlying Cathy R. Smith’s Boston Scientific (BSX) deferred units be delivered?

Shares underlying the deferred stock units will be issued after her separation from Board service. Delivery occurs in accordance with Boston Scientific’s Non-Employee Director Deferred Compensation Plan, rather than immediately upon vesting at the annual meeting.

What does each deferred stock unit represent in Cathy R. Smith’s Boston Scientific (BSX) Form 4?

Each deferred stock unit represents a commitment to issue one share of Boston Scientific common stock. The units function as deferred equity, aligning director compensation with shareholder interests while postponing share delivery until after Board service ends.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 07:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Cathy R

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	03/02/2026		A		556		(2)	(3)	Common Stock	556	$0.0000	556	D
Deferred Stock Units	(1)	03/02/2026		A		323		(3)	(3)	Common Stock	323	$0.0000	879	D

Explanation of Responses:

1. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

2. Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $42,419.50 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

3. Grant of deferred stock units in lieu of 100% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

	/s/ Susan Thompson, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.